Wiskott-Aldrich syndrome program (University College London)

N/A

Report date: 2025/09/05 14:00:02

Base Information

Drug NameWiskott-Aldrich syndrome program (University College London)

Drug Alias NameN/A

ClassificationCell and gene therapy > Gene therapy > Gene editing > CRISPR > CRISPR-Cas9Cell and gene therapy > Cell therapy > Stem cell therapy > Hematopoietic stem cells therapy

Mechanisms of ActionWASp gene transference

TargetsWiskott-Aldrich syndrome protein

Therapy Area/IndicationsWiskott-Aldrich Syndrome

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited Kingdom

CombinationsNo

Global Highest StatusPreclinical

Highest Status in ChinaN/A

Originator CompaniesUniversity College London

China Registration ClassN/A

Develop Information

Active CompaniesUniversity College London

Inactive CompaniesN/A

Active IndicationsWiskott-Aldrich Syndrome

Inactive IndicationsN/A

Other Information

ATC CodeN/A